Indusatumab vedotin

Drug Profile

Indusatumab vedotin

Alternative Names: GCC antibody drug conjugate; MLN-0264; TAK-264

Latest Information Update: 22 May 2017

Price : $50

At a glance

  • Originator Millennium
  • Developer Takeda Oncology
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Guanylate cyclase C antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Gastrointestinal cancer; Pancreatic cancer

Most Recent Events

  • 06 Apr 2017 Millennium Pharmaceuticals terminated a phase II trial due to a business decision in Pancreatic cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA, Italy, Belgium, Spain and United Kingdom (IV) (NCT02202785)
  • 16 Apr 2016 Interim efficacy and adverse events data from a phase II trial in Pancreatic cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top